Grail Inc · Q3 2024 earnings

Briefing

GRAIL's third quarter of 2024 financial results were reported, featuring a 52% year-over-year growth in Galleri revenue, which reached $25.4 million, and commercial Galleri sales surpassing 250,000 tests since launch, with a cash balance of $853.6 million providing runway into 2028.

GRAIL reported a 38% increase in total revenue to $28.7 million, with Galleri revenue growing by 52% to $25.4 million. The company's net loss was $125.7 million, while adjusted EBITDA showed an improvement. Over 250,000 Galleri tests have been sold since launch, and the company is focusing on cost management and advancing registrational studies.

• Total revenue increased by 38% year-over-year to $28.7 million.
• Galleri revenue grew by 52% year-over-year to $25.4 million.
• Net loss was $125.7 million, including amortization and restructuring charges.
• Cash and cash equivalents totaled $853.6 million as of September 30, 2024.

Headline financials

Revenue & EPS history

The press release contains forward-looking statements regarding GRAIL's future financial performance, products, clinical studies, regulatory compliance, market opportunity, growth strategies, and cash sufficiency. These statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially.